Please login to the form below

Not currently logged in

Excellence in Patient Education and Support

Sponsored by

Back to Results


One Heart support programme

by AstraZeneca UK
with support from Atlantis Healthcare

Summary of work

NICE guidelines recommend that patients take oral antiplatelet (OAP) medication for one year post myocardial infarction (MI). However, research conducted with clopidogrel patients has shown that Acute Coronary Syndromes (ACS) patients who discontinue their oral antiplatelet  treatment within 12 months of discharge almost double their risk of dying or having a non-fatal heart attack. (1). Yet almost half of all patients discontinue their OAP treatment within 12 months of discharge from hospital. (1) Data clearly shows the risks to patients through poor adherence to oral antiplatelet therapy. (2)

OneHeart is a free, multichannel patient support programme, developed by Atlantis Healthcare for AstraZeneca UK in collaboration with the NHS. It has been designed to help ACS patients achieve better heart health and increase persistence to prescribed OAP medication utilising a broad range of personalised interventional communications which are delivered at several points along a patient’s journey throughout the OneHeart programme.

The programme is a true example of effective collaboration between pharma and the NHS, and has shown positive impact on patients’ adherence and persistence, lifestyle changes and confidence in managing their condition. Patients have also indicated a high degree of satisfaction with the programme experience overall. (3)

1. Boggon R, van Staa TP, Timmis A, Hemingway H, Ray KK, Begg A, Emmas C, Fox KAA. (2011). Clopidogrel Discontinuation After Acute Coronary Syndromes: Frequency, Predictors and Associations with Death and Myocardial Infarctions. A hospital registry-primary care linked cohort (MINAP-GPRD).

2. Sud A, Kline-Rogers EM, Eagle KA, et al. (2005). Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother. 2005; 39:1792–7.

3. Market research conducted by Atlantis Healthcare (2014).

Judges' comments

The One Heart programme was available to ALL ACS patients where deployed, and is a great example of effective collaboration between pharma and the NHS. Based on insight from quantitative and qualitative research, the multi-channel approach was very effective for this high risk patient group - achieving a 97% persistence rate at 24 weeks, significant lifestyle improvements and increased patient confidence in managing their condition. A truly impressive patient support campaign.

Highly commended

Assure patient support programme (Asacol®) - by Actavis and Allergan UK
with support from Atlantis Healthcare

Highly commended


Don’t Turn Your Back On It (Global) - by AbbVie
with support from Biosector 2

Positive Conversations - by Gilead
with support from inVentiv Medical Communications

SymTrac – A master class in patient-centred programme design - by Novartis
with support from Aurora

Rethinking Hepatitis - by World Hepatitis Alliance
with support from Ketchum

Key dates

Entry deadline 26 August 2021
Extended entry deadline 2 September 2021*
*additional fee applies
Judging Day 1 October 2021
Company of the Year Interviews 22 October 2021
PMEA Event 24 November 2021